IMAP is pleased to announce IMAP Morocco’s involvement in another successful transaction, advising Valstar Investment on the strategic sale of the entire stake in Luxembourg-based Valstar S.A. (“Valstar”) to Sun Pharma, granting Sun Pharma with complete ownership of Kemipharm, an African specialty generic pharmaceutical firm. Kemipharm's operations include a tablet and capsule manufacturing facility located in Casablanca, Morocco.

Sun Pharma, a preeminent Indian pharmaceutical giant, is the fourth largest global specialty generic pharmaceutical company with a presence in more than 100 countries.

This transaction is a strategic expansion move that aligns with Sun Pharma's commitment to enhancing its global footprint and strengthening its market presence in rapidly growing regions such as Africa. This acquisition not only boosts Sun Pharma’s manufacturing capabilities and product range but also provides it with critical access to the dynamic African pharmaceutical market.

The team from IMAP Morocco (Ascent Capital Partners), led by Abdellatif Imani and Mehdi Berbich, was delighted to advise Valstar Investment on this transaction. The transaction underscores IMAP Morocco’s expertise in the pharmaceutical sector and its strategic focus on cross-border transactions.